The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Ozempic, MRI machines and flat screen televisions all emerged out of fundamental research decades earlier — the very types of ...

And I do have several favorite stocks that fit that description. My top growth stock to buy in November is one that I've ...

Cells contain a blueprint in the form of DNA that dictates what they can make. This blueprint is converted into a message ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its third-quarter 2025 results on Nov. 3, after ...

A study reveals how RNA modifications regulate the transformation of stem cells into retinal cells. The protein METTL3, which ...

NLS Pharmaceutics Ltd. ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd. ("Kadimastem"), a clinical-stage ...

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics ...

Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for coronary artery disease, though its precise role in disease progression continues to emerge. This study leverages ...